Protein kinase Cα: disease regulator and therapeutic target

Trends in Pharmacological Sciences

Volumn 31, Issue 1, 2010, Pages 8-14

  Konopatskaya, Olga ^a   Poole, Alastair W ^a  

^a SCHOOL OF MEDICAL SCIENCES   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

12 (2 CYANOETHYL) 6,7,12,13 TETRAHYDRO 13 METHYL 5 OXOINDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE; ALPHA ACTIN; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; APOLIPOPROTEIN C3; ATRIAL NATRIURETIC FACTOR; BETA1 INTEGRIN; BRYOSTATIN; CALCINEURIN; CALPHOSTIN C; CD31 ANTIGEN; CHELERYTHRINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENZASTAURIN; GELATINASE A; ISIS 3521; KAI 9803; LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN; PADGEM PROTEIN; PHOSPHOLIPASE C; PROTEIN KINASE C ALPHA; PROTEIN KINASE C INHIBITOR; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RUBOXISTAURIN; TRANSIENT RECEPTOR POTENTIAL CHANNEL 1; TROPONIN I; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULAR ENDOTHELIAL CADHERIN; VASCULOTROPIN;

ADVANCED CANCER; ANTISENSE THERAPY; ARTERY THROMBOSIS; ARTICLE; ATHEROGENESIS; CELL ADHESION; CELL PROLIFERATION; CLINICAL TRIAL; DIABETIC RETINOPATHY; DRUG EFFICACY; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG TARGETING; DRUG TOLERABILITY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME REGULATION; ENZYME STRUCTURE; HEART FAILURE; HEART INFARCTION; HEART MUSCLE CONTRACTILITY; HUMAN; LUNG CANCER; MONOCYTE; NEOPLASM; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; THROMBOCYTE FUNCTION; UNSPECIFIED SIDE EFFECT; ANIMAL; CARDIOVASCULAR DISEASE; DISEASE MODEL; DRUG DELIVERY SYSTEM; DRUG EFFECT; METABOLISM; MOUSE; MOUSE MUTANT; PATHOPHYSIOLOGY; REVIEW; THROMBOSIS;

ANIMALS; CARDIOVASCULAR DISEASES; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; HUMANS; MICE; MICE, KNOCKOUT; NEOPLASMS; PROTEIN KINASE C-ALPHA; THROMBOSIS;

EID: 72749088774     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2009.10.006     Document Type: Article

References (84)

1. Parker P.J., and Murray-Rust J. PKC at a glance. J. Cell Sci. 117 (2004) 131-132
2. Oster H., and Leitges M. Protein kinase Cα but not PKCζ suppresses intestinal tumor formation in ApcMin/+ mice. Cancer Res. 66 (2006) 6955-6963
3. Braz J.C., et al. PKCα regulates cardiac contractility and propensity toward heart failure. Nat. Med. 10 (2004) 248-254
4. Konopatskaya O., et al. PKCα regulates platelet granule secretion and thrombus formation in mice. J. Clin. Invest. 119 (2009) 399-407
5. Churchill E., et al. PKC isozymes in chronic cardiac disease: possible therapeutic targets?. Annu. Rev. Pharmacol. Toxicol. 48 (2008) 569-599
6. Palaniyandi S.S., et al. Protein kinase C in heart failure: a therapeutic target?. Cardiovasc. Res. 82 (2009) 229-239
7. Mackay H.J., and Twelves C.J. Targeting the protein kinase C family: are we there yet?. Nat. Rev. Cancer 7 (2007) 554-562
8. Dempsey E.C., et al. Protein kinase C isozymes and the regulation of diverse cell responses. Am. J. Physiol. Lung Cell Mol. Physiol. 279 (2000) L429-438
9. Gould C.M., and Newton A.C. The life and death of protein kinase C. Curr. Drug Targets 9 (2008) 614-625
10. Nakashima S. Protein kinase Cα (PKCα): regulation and biological function. J. Biochem. 132 (2002) 669-675
11. Leitges M., et al. Knockout of PKCα enhances insulin signaling through PI3K. Mol. Endocrinol. 16 (2002) 847-858
12. Pfeifhofer C., et al. Defective IgG2a/2b class switching in PKCα-/- mice. J. Immunol. 176 (2006) 6004-6011
13. von Essen M., et al. Protein kinase C (PKC) α and PKCθ are the major PKC isotypes involved in TCR down-regulation. J. Immunol. 176 (2006) 7502-7510
14. Vijayan K., et al. Protein kinase Cα-induced hypertrophy of neonatal rat ventricular myocytes. Am. J. Physiol. Heart Circ. Physiol. 287 (2004) H2777-2789
15. Kerkela R., et al. Identification of PKCα isoform-specific effects in cardiac myocytes using antisense phosphorothioate oligonucleotides. Mol. Pharmacol. 62 (2002) 1482-1491
16. Braz J.C., et al. PKCα regulates the hypertrophic growth of cardiomyocytes through extracellular signal-regulated kinase1/2 (ERK1/2). J. Cell Biol. 156 (2002) 905-919
17. Belin R.J., et al. Augmented protein kinase Cα-induced myofilament protein phosphorylation contributes to myofilament dysfunction in experimental congestive heart failure. Circ. Res. 101 (2007) 195-204
18. Sumandea M.P., et al. Identification of a functionally critical protein kinase C phosphorylation residue of cardiac troponin T. J. Biol. Chem. 278 (2003) 35135-35144
19. Holm P.W., et al. Atherosclerotic plaque development and instability: a dual role for VEGF. Ann. Med. 41 (2009) 257-264
20. Rask-Madsen C., and King G.L. Differential regulation of VEGF signaling by PKCα and PKCε in endothelial cells. Arterioscler Thromb. Vasc. Biol. 28 (2008) 919-924
21. Xia P., et al. Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J. Clin. Invest. 98 (1996) 2018-2026
22. Goekjian P.G., and Jirousek M.R. Protein kinase C inhibitors as novel anticancer drugs. Expert Opin. Investig. Drugs 10 (2001) 2117-2140
23. Wang A., et al. Inhibition of protein kinase Cα prevents endothelial cell migration and vascular tube formation in vitro and myocardial neovascularization in vivo. Circ. Res. 90 (2002) 609-616
24. Xu H., et al. Protein kinase Cα promotes angiogenic activity of human endothelial cells via induction of vascular endothelial growth factor. Cardiovasc. Res. 78 (2008) 349-355
25. Harrington E.O., et al. Endothelial proliferation, migration, and differentiation are blunted by conditionally expressed protein kinase C pseudosubstrate peptides. Biochem. Biophys Res. Commun. 271 (2000) 499-508
26. Mountain D.J., et al. Interleukin-1beta increases expression and activity of matrix metalloproteinase-2 in cardiac microvascular endothelial cells: role of PKCalpha/beta1 and MAPKs. Am. J. Physiol. Cell Physiol. 292 (2007) C867-875
27. Aghajanian A., et al. Endothelial cell junctions and the regulation of vascular permeability and leukocyte transmigration. J. Thromb. Haemost. 6 (2008) 1453-1460
28. Lum H., and Malik A.B. Regulation of vascular endothelial barrier function. Am. J. Physiol. 267 (1994) L223-241
29. Sandoval R., et al. Ca(2+) signalling and PKCα activate increased endothelial permeability by disassembly of VE-cadherin junctions. J. Physiol. 533 (2001) 433-445
30. Tiruppathi C., et al. Role of Ca2+ signaling in the regulation of endothelial permeability. Vascul. Pharmacol. 39 (2002) 173-185
31. Ahmmed G.U., et al. Protein kinase Cα phosphorylates the TRPC1 channel and regulates store-operated Ca2+ entry in endothelial cells. J. Biol. Chem. 279 (2004) 20941-20949
32. Mehta D., et al. Protein kinase C-alpha signals rho-guanine nucleotide dissociation inhibitor phosphorylation and rho activation and regulates the endothelial cell barrier function. J. Biol. Chem. 276 (2001) 22614-22620
33. Stamatovic S.M., et al. Protein kinase Calpha-RhoA cross-talk in CCL2-induced alterations in brain endothelial permeability. J. Biol. Chem. 281 (2006) 8379-8388
34. Ferro T., et al. Protein kinase C-alpha mediates endothelial barrier dysfunction induced by TNF-alpha. Am. J. Physiol. Lung Cell Mol. Physiol. 278 (2000) L1107-1117
35. Lum H., et al. Protein phosphatase 2B inhibitor potentiates endothelial PKC activity and barrier dysfunction. Am. J. Physiol. Lung Cell Mol. Physiol. 281 (2001) L546-555
36. Hempel A., et al. High glucose concentrations increase endothelial cell permeability via activation of protein kinase C alpha. Circ. Res. 81 (1997) 363-371
37. Witztum J.L., and Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J. Clin. Invest. 88 (1991) 1785-1792
38. Fleming I., et al. Oxidized low-density lipoprotein increases superoxide production by endothelial nitric oxide synthase by inhibiting PKCalpha. Cardiovasc. Res. 65 (2005) 897-906
39. Takahashi K., et al. SDF-1-induced adhesion of monocytes to vascular endothelium is modulated by azelnidipine via protein kinase C inhibition. Eur. J. Pharmacol. 552 (2006) 162-169
40. Kawakami A., et al. Apolipoprotein CIII-induced THP-1 cell adhesion to endothelial cells involves pertussis toxin-sensitive G protein- and protein kinase C alpha-mediated nuclear factor-kappaB activation. Arterioscler Thromb. Vasc. Biol. 27 (2007) 219-225
41. Gong N., et al. Lactosylceramide recruits PKCalpha/epsilon and phospholipase A2 to stimulate PECAM-1 expression in human monocytes and adhesion to endothelial cells. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 6490-6495
42. Fu J., et al. Protease-activated receptor-1 activation of endothelial cells induces protein kinase Calpha-dependent phosphorylation of syntaxin 4 and Munc18c: role in signaling p-selectin expression. J. Biol. Chem. 280 (2005) 3178-3184
43. Meadows T.A., and Bhatt D.L. Clinical aspects of platelet inhibitors and thrombus formation. Circ. Res. 100 (2007) 1261-1275
44. Harper M.T., and Poole A.W. Isoform-specific functions of protein kinase C: the platelet paradigm. Biochem. Soc. Trans. 35 (2007) 1005-1008
45. Yoshioka A., et al. Identification of protein kinase Calpha as an essential, but not sufficient, cytosolic factor for Ca2+-induced alpha- and dense-core granule secretion in platelets. J. Biol. Chem. 276 (2001) 39379-39385
46. Tabuchi A., et al. Direct demonstration of involvement of protein kinase Calpha in the Ca2+-induced platelet aggregation. J. Biol. Chem. 278 (2003) 26374-26379
47. Pula G., et al. Functional interaction of protein kinase Calpha with the tyrosine kinases Syk and Src in human platelets. J. Biol. Chem. 280 (2005) 7194-7205
48. Han J., et al. Reconstructing and deconstructing agonist-induced activation of integrin alphaIIbbeta3. Curr. Biol. 16 (2006) 1796-1806
49. Fields A.P., and Murray N.R. Protein kinase C isozymes as therapeutic targets for treatment of human cancers. Adv. Enzyme Regul. 48 (2008) 166-178
50. Koivunen J., et al. Protein kinase C alpha/beta inhibitor Go6976 promotes formation of cell junctions and inhibits invasion of urinary bladder carcinoma cells. Cancer Res. 64 (2004) 5693-5701
51. Masur K., et al. High PKC alpha and low E-cadherin expression contribute to high migratory activity of colon carcinoma cells. Mol. Biol. Cell 12 (2001) 1973-1982
52. Fournier D.B., et al. Protein kinase C alpha expression is inversely related to ER status in endometrial carcinoma: possible role in AP-1-mediated proliferation of ER-negative endometrial cancer. Gynecol. Oncol. 81 (2001) 366-372
53. Koren R., et al. Expression of protein kinase C isoenzymes in benign hyperplasia and carcinoma of prostate. Oncol. Rep. 11 (2004) 321-326
54. Langzam L., et al. Patterns of protein kinase C isoenzyme expression in transitional cell carcinoma of bladder. Relation to degree of malignancy. Am. J. Clin. Pathol. 116 (2001) 377-385
55. Varga A., et al. Tumor grade-dependent alterations in the protein kinase C isoform pattern in urinary bladder carcinomas. Eur. Urol. 46 (2004) 462-465
56. Lahn M., et al. The role of protein kinase C-alpha in hematologic malignancies. Acta Haematol. 115 (2006) 1-8
57. Neill G.W., et al. Loss of protein kinase Calpha expression may enhance the tumorigenic potential of Gli1 in basal cell carcinoma. Cancer Res. 63 (2003) 4692-4697
58. Lahn M., et al. Protein kinase C alpha expression in breast and ovarian cancer. Oncology 67 (2004) 1-10
59. Tan M., et al. Upregulation and activation of PKC alpha by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by combined treatment with PKC alpha and Src inhibitors. Oncogene 25 (2006) 3286-3295
60. Kerfoot C., et al. Immunohistochemical analysis of advanced human breast carcinomas reveals downregulation of protein kinase C alpha. J. Histochem. Cytochem. 52 (2004) 419-422
61. Hanauske A.R., et al. The role of protein kinase C-alpha (PKC-alpha) in cancer and its modulation by the novel PKC-alpha-specific inhibitor aprinocarsen. Curr. Pharm. Des. 10 (2004) 1923-1936
62. Li K., and Zhang J. ISIS-3521. Isis Pharmaceuticals. Curr. Opin. Investig. Drugs 2 (2001) 1454-1461
63. Villalona-Calero M.A., et al. A phase I/II study of LY900003, an antisense inhibitor of protein kinase C-alpha, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer. Clin. Cancer Res. 10 (2004) 6086-6093
64. Marshall J.L., et al. A phase II trial of ISIS 3521 in patients with metastatic colorectal cancer. Clin. Colorectal. Cancer 4 (2004) 268-274
65. Advani R., et al. A Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with advanced ovarian carcinoma. Cancer 100 (2004) 321-326
66. Roychowdhury D., and Lahn M. Antisense therapy directed to protein kinase C-alpha (Affinitak, LY900003/ISIS 3521): potential role in breast cancer. Semin Oncol. 30 (2003) 30-33
67. Tolcher A.W., et al. A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer. Clin. Cancer Res. 8 (2002) 2530-2535
68. Rao S., et al. Phase II study of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C alpha, in patients with previously treated low-grade non-Hodgkin's lymphoma. Ann. Oncol. 15 (2004) 1413-1418
69. Paz-Ares L., et al. Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer. J. Clin. Oncol. 24 (2006) 1428-1434
70. Roffey J., et al. Protein kinase C intervention: the state of play. Curr. Opin. Cell Biol. 21 (2009) 268-279
71. Cole D.C., et al. Identification, characterization and initial hit-to-lead optimization of a series of 4-arylamino-3-pyridinecarbonitrile as protein kinase C theta (PKCtheta) inhibitors. J. Med. Chem. 51 (2008) 5958-5963
72. Liu Q., et al. Protein Kinase C{alpha}, but Not PKC{beta} or PKC{gamma}, Regulates Contractility and Heart Failure Susceptibility. Implications for Ruboxistaurin As a Novel Therapeutic Approach. Circ. Res. 105 (2009) 194-200
73. Chen Y.B., and LaCasce A.S. Enzastaurin. Expert Opin. Investig. Drugs 17 (2008) 939-944
74. Das Evcimen N., and King G.L. The role of protein kinase C activation and the vascular complications of diabetes. Pharmacol. Res. 55 (2007) 498-510
75. Rademaker-Lakhai J.M., et al. Phase I pharmacokinetic and pharmacodynamic study of the oral protein kinase C beta-inhibitor enzastaurin in combination with gemcitabine and cisplatin in patients with advanced cancer. Clin. Cancer Res. 13 (2007) 4474-4481
76. Herbert J.M., et al. Chelerythrine is a potent and specific inhibitor of protein kinase C. Biochem. Biophys Res. Commun. 172 (1990) 993-999
77. Szallasi Z., et al. Differential regulation of protein kinase C isozymes by bryostatin 1 and phorbol 12-myristate 13-acetate in NIH 3T3 fibroblasts. J. Biol. Chem. 269 (1994) 2118-2124
78. Wender P.A., et al. Function-oriented synthesis, step economy, and drug design. Acc. Chem. Res. 41 (2008) 40-49
79. Bruns R.F., et al. Inhibition of protein kinase C by calphostin C is light-dependent. Biochem. Biophys Res. Commun. 176 (1991) 288-293
80. Poole A.W., et al. PKC-interacting proteins: from function to pharmacology. Trends Pharmacol. Sci. 25 (2004) 528-535
81. Churchill E.N., et al. Rationally designed peptide regulators of protein kinase C. Trends Endocrinol. Metab. 20 (2009) 25-33
82. Bates E., et al. Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. Circulation 117 (2008) 886-896
83. Martelli A.M., et al. Molecular characterization of protein kinase C-alpha binding to lamin A. J. Cell Biochem. 86 (2002) 320-330
84. Tabellini G., et al. Binding of elements of protein kinase C-alpha regulatory domain to lamin B1. Cell Signal. 14 (2002) 819-827